Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活

2021-02-03 国际文传国际文传

通过第二项资产扩展GABA-A调节剂管道

Engrail Therapeutics™（Engrail）（公司）今日宣布收购生物医药公司NeuroCycle Therapeutics，该公司致力于开发存在人体脑部的抑制性神经传递物GABA-A受体，此项收购继续巩固Engrail于GABA-A范畴的领先地位，并为2021年多个进行中的临床试验提供强而有力的平台。

Engrail Therapeutics首席执行官兼总裁Vikram Sudarsan博士说：「Engrail灵活的交易模式及『科学至上』的方法，让我们能够以较低风险的市场途径获取高质素资产。与此同时，我们完整地结合临床开发的策略、监管规例以及对知识产权的全面了解，从而找到具有经过验证作用机制的差异资产。 GABA-A的效果已经充分得以验证，该神经递质的调节剂可以在广泛的神经病学和精神病学病症中发挥治疗作用。我们现在已经拥有多种具有强大特性的BA-A调节剂，并期望快速推进发展步伐。」

Vikram Sudarsan博士续说：「我们将继续致力于建立领先和以患者为中心的神经科学公司，并通过专利授权、共同开发和收购渠道不断壮大。我们的目标是在未来几年内建立多样化的神经科学治疗方法，NeuroCycle的收购正正代表了我们在这条发展道路上的重要一环。我们预计2021年将是繁忙的一年，因我们打算增加更多的交易以扩大我们的资产组合。」

NeuroCycle总裁Jed Hubbs博士说：「NeuroCycle一直专注于GABA-A空间并拥有丰富的经验，Engrail的收购将承继NeuroCycle已开展的工作，我们深信这绝对是一个理想公司的模式。同时我们期待看到Engrail为需要的患者带来新药。」

关于Engrail Therapeutics

Engrail成立于2019年，致力于为降低神经系统疾病的给病人及社会带来的压力而开辟新方向。我们将生物学的见解与可行的临床解决方案结合起来，构建并推进多种变革型的药物组合。我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品。 Engrail由南丰生命科技提供长期资本承诺。

原文阅读：http://www.businesswirechina.com/zh/news/45671.html

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (10)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2022-01-10 ms24272190615788285182

#Therapeutic#

66 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-22 124988c7m106暂无昵称

#ERA#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-07-25 spoonycyy

#Eng#

34 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-05-09 feather89

#PE#

26 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-04 linlin2312

#ROC#

27 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-16 hmwwww

#疾病患者#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-05 luoxiaog

#神经系统#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-05 zhaojie88

#therapeutics#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-05 smlt2015

#中枢神经#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1974399, encodeId=111919e43999d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jan 10 12:25:01 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739037, encodeId=95271e390371e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 22 03:25:01 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081607, encodeId=3f51208160ef8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 25 17:25:01 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728813, encodeId=4e421e2881396, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun May 09 22:25:01 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977032, encodeId=994919e70321c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu Feb 04 06:25:01 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799141, encodeId=3cf71e99141a2, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Feb 16 07:25:01 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283164, encodeId=ffb21283164cf, content=<a href='/topic/show?id=4fade445192' target=_blank style='color:#2F92EE;'>#神经系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74451, encryptionId=4fade445192, topicName=神经系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350849, encodeId=b2eb1350849d8, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624271, encodeId=0c2a16242e158, content=<a href='/topic/show?id=a9b2222e60a' target=_blank style='color:#2F92EE;'>#中枢神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22276, encryptionId=a9b2222e60a, topicName=中枢神经)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fcf20658765, createdName=smlt2015, createdTime=Fri Feb 05 06:25:01 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922568, encodeId=7390922568d6, content=我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:22:42 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
2021-02-03 Aidy

我们利用严谨的科学方法来确定最有潜力的治疗方法，利用灵活的交易模式来推进那些作用机制已被证实的资产，并有效地将其转化为商业化产品

75 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

报道

Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活

相关资讯

拓展阅读

科室

工具

服务